Prior authorization for HCPCS/J-codes

Authorization is required for administration of ESAs and related HCPCS/J-codes; specific HCPCS/J-codes are payable only if selection/coverage criteria are met.

• Covered HCPCS/J-codes include J0885, J0887, J0888, Q4081, Q5105, Q5106, S9537, J0881, J0882, J0890, J2916 when selection/coverage criteria are documented.

Prior authorization for ESA therapy

Prior authorization must confirm the FDA‑indicated diagnosis (e.g., CKD-related anemia, zidovudine-treated HIV with low endogenous EPO, or chemotherapy‑induced anemia with at least two additional months of planned myelosuppressive chemotherapy) and document that therapy will use the lowest dose sufficient to avoid transfusion per labeling.

• Chemotherapy-induced anemia: hemoglobin < 10 g/dL and ≥2 months planned chemotherapy required for initiation.
• CKD and perioperative indications must be consistent with FDA labeling and product-specific dosing.

Hemoglobin/hematocrit monitoring requirement

Documentation of serial hemoglobin/hematocrit is required; regulatory/payer guidance requires dose reduction or interruption when Hb/Hct exceed specified thresholds in ESRD patients receiving dialysis.

• CMS monitoring: hematocrit >39.0% or hemoglobin >13.0 g/dL for 3+ consecutive billing cycles triggers dose/payment adjustments.
• Follow FDA guidance to reduce or withhold ESA dose if hemoglobin approaches or exceeds 11 g/dL (non-dialysis) or exceeds 11 g/dL (dialysis patients per labeling guidance).

Prior authorization for ESA use

Prior authorization must ensure ESA prescribing aligns with FDA labeling (use only for indicated diagnoses, dosing per product label, and avoidance of ESA use when cure is the anticipated outcome).

• Do not initiate ESAs for patients receiving myelosuppressive chemotherapy if the anticipated outcome is cure.
• Use the lowest dose necessary to avoid RBC transfusion and discontinue in non-responders after 6–8 weeks.

Prior authorization requirements for ESAs

Prior authorization requests must include documentation of the indication, current hemoglobin, iron evaluation and correction, and prior therapies before approving ESA therapy.

• Required: baseline hemoglobin, transferrin saturation and ferritin, folate/B12 status, transfusion history, and chemotherapy plan (if applicable).
• For cancer-related use, document risk/benefit discussion including thromboembolism and hypertension risks.

Prior authorization considerations for ESA trials

Prior authorization for ESA trials should reflect recommended trial periods and monitoring (e.g., guideline-supported MDS trial up to 16 weeks) and consider thrombosis risk and dose‑holding rules.

• MDS: trial structure—8 weeks at starting dose ± G-CSF, then up to 8 weeks at higher dose; continue only if erythroid response achieved.
• Utilization review may require documentation of planned trial duration and response assessments.

Preoperative rHuEPO + iron — authorization considerations

Authorization for preoperative rHuEPO plus iron should require documentation of the anemia diagnosis, planned dosing intent (high vs low dose), and concurrent iron therapy, since combined rHuEPO + iron reduced perioperative transfusion in trials.

• Document that concurrent iron supplementation will be provided and the clinical goal is reduction of RBC transfusion.
• Consider cost‑effectiveness and reserve routine preoperative ESA use for select high‑risk cases with documented rationale.

Prior authorization: FDA‑approved indications

Prior authorization must be supported by FDA‑approved indications and brand labeling (CKD, zidovudine‑treated HIV with low EPO, chemotherapy‑induced anemia with ≥2 additional months planned chemotherapy, or perioperative reduction of transfusion in specified surgical patients).

• Mircera, Aranesp, Epogen/Procrit/Retacrit listed in FDA-approved indications appendix.
• Off‑label uses require strong justification and supporting evidence.

No PA rules in this section

This reference section lists prescribing information and guideline citations but does not itself establish additional prior authorization rules; follow the policy's authorization module for requirements.

Prior authorization and policy review

Follow Aetna policy and prior authorization procedures as posted; policy is maintained and reviewed by Aetna and should guide coverage determinations.

• Policy last reviewed 01/09/2024; next review 11/14/2024.

Product conversion/step guidance

Document prior ESA dosing and dosing rationale when converting between products (use provided conversion tables for epoetin alfa → darbepoetin and Mircera conversion guidance).

• Include previous epoetin alfa weekly dose when calculating darbepoetin or Mircera starting dose per Appendix C and product labeling.
• Provide rationale for frequency change (eg, switching to less frequent Mircera dosing when Hb stabilized).

Step/conversion guidance

When requesting conversion or longer‑interval products (eg, Mircera) for CKD-related anemia, document that hemoglobin was stable on prior ESA and provide the conversion calculation per manufacturer guidance.

• Mircera is not indicated for chemotherapy‑induced anemia; conversions apply primarily in CKD contexts.
• Provide evidence of stable Hb (±1 g/dL) before conversion consideration.

Trial-preferred use for cancer-related anemia

For chemotherapy‑induced anemia, NICE advised ESA use only within clinical trials due to uncertain survival and thromboembolism effects; document when trial participation is applicable.

• NICE assessment noted modest transfusion reductions but uncertain effects on survival; consider trial enrollment where relevant.

Step to transfusion/conservative care

Prior authorization reviewers should consider RBC transfusion and conservative management as alternatives and require documentation that less‑risk options (iron therapy, transfusion) were considered prior to ESA initiation.

• Document trials of iron therapy (IV or oral) and any recent transfusion history.
• ESAs should be used at the lowest effective dose to minimize attained hemoglobin and thrombotic risk.

Step therapy: trial of iron or transfusion-first strategies

For cancer patients, document that iron status was assessed and corrected as appropriate and that transfusion‑first or iron‑first strategies were considered before initiating ESAs.

• Provide transferrin saturation, ferritin, and any iron therapy given.
• Rationale for ESA vs iron/transfusion should be explicit in the prior authorization record.

Stepwise ESA trial in MDS

For MDS, prior authorization should reflect guideline‑recommended stepwise ESA trial: initial 8 weeks at starting dose (± G‑CSF) then up to 8 additional weeks at higher dose for non‑responders before deeming failure.

• Document IPSS risk (low or INT‑1), symptomatic anemia, predictive response score, trial start date, and planned response assessments.
• Continue ESA only if complete/partial erythroid response achieved; use minimum effective dose.

Step therapy and cost-effectiveness note

Routine preoperative ESA use for elective surgery is not considered cost‑effective; prior authorization should reserve ESAs for select high‑risk cases after iron trial and documented rationale.

• Require documentation of why IV iron or other PBM measures are insufficient and the expected benefit of ESA therapy.

Perioperative management preference

Perioperative anemia management prioritizes IV iron and treatment of underlying causes; ESAs are not standard perioperative management and require justification if requested.

• Document iron indices and rationale for ESA if IV iron alone is inadequate.
• Provide planned blood conservation measures (eg, cell saver) when preoperative ESA use is proposed.

No step therapy requirements are specifi

No specific step therapy mandates are listed in the references; however, guideline citations (KDIGO, NCCN, ASCO/ASH) in the policy inform preferred sequencing and authorization decisions.

• Use referenced guideline recommendations to inform sequencing when evaluating prior authorization requests.

Guideline-informed sequencing

Guideline and compendium references (NCCN, ASCO/ASH, SEOM) should be used to inform preferred sequencing and alternatives to ESAs when evaluating authorization requests.

• NCCN Hematopoietic Growth Factors guidance and compendia entries (Aranesp, epoetin alfa) are referenced for oncology use.

Documentation for chemotherapy-induced anemia

For chemotherapy‑induced anemia prior authorization, include documentation of hemoglobin (< 10 g/dL) and evidence of at least two additional months of planned myelosuppressive chemotherapy.

• Document chemotherapy regimen, planned duration (≥2 months), and hemoglobin value at initiation.
• Confirm discussion of risks/benefits and plan for monitoring Hb response.

Documentation for conversions and dosing

When converting products, prior authorization must include dosing rationale and record of prior ESA dosing used for conversion calculations (eg, epoetin alfa weekly dose to darbepoetin or Mircera conversion).

• Append conversion table entries or manufacturer guidance to support dose calculations.
• Include date and dose of most recent ESA administrations.

Required baseline and monitoring data

Required documentation for prior authorization must include baseline and on‑therapy hemoglobin, iron studies (transferrin saturation and ferritin), folate and B12 status, concomitant chemotherapy plan when applicable, and prior PRCA/neutralizing antibody history.

• Transferrin saturation ≥ 20% and ferritin ≥ 100 ng/mL are expected before initiation when feasible.
• Include transfusion history and planned monitoring schedule.

ESA dosing/payment monitoring for ESRD

For ESRD patients on dialysis, prior authorization/claims require hematocrit/hemoglobin monitoring records because CMS applies payment and dosing adjustments for hematocrit >39% (or Hb >13.0 g/dL) over multiple billing cycles.

• Provide serial Hct/Hb values across billing cycles to support dosing and payment adjudication.
• Be prepared for CMS‑based dose reduction/payment limitations if thresholds exceeded for 3+ consecutive cycles.

Document Hgb, indication, and response

Document hemoglobin values, indication, shared decision‑making discussion of risks/benefits, dosing per FDA label, and an evaluation of response within 6–8 weeks to justify continuation or discontinuation.

• For non‑responders after 6–8 weeks, document decision to discontinue ESA.
• Record any dose adjustments and Hb trends (eg, increases >1 g/dL in 2 weeks).

Required clinical documentation for cancer-related use

For cancer‑related ESA use prior authorization, include hemoglobin levels, iron assessment and correction, chemotherapy schedule and intent (curative vs palliative), transfusion history, and explicit rationale given ESA risks.

• Hemoglobin threshold for initiation generally <10 g/dL; ensure at least two additional months of planned myelosuppressive chemotherapy.
• Document discussion of thromboembolic and hypertension risks and plan for monitoring.

Preoperative pediatric documentation

For preoperative pediatric craniosynostosis ESA use, prior authorization must include the indication, detailed preoperative EPO dosing schedule, iron supplementation plan, planned surgery date, transfusion alternatives and blood‑conservation measures.

• Provide baseline and anticipated preoperative Hb/Hct and the protocol for intra‑operative cell salvage and transfusion triggers.

MDS documentation for ESA trial

For MDS ESA trials, prior authorization should include IPSS risk (low or INT‑1), symptomatic anemia documentation, predictive score for ESA response, planned trial duration and response assessment schedule.

• Document phenotype (sideroblastic vs non‑sideroblastic) and whether G‑CSF will be combined with ESA if indicated.
• Limit trial to maximum 16 weeks per guideline (8+8 week strategy).

Required clinical documentation for ESA consideration

For ESA consideration in MDS/myelofibrosis, include IPSS risk category, predictive response score, phenotype, transfusion dependence status, baseline hemoglobin and serum erythropoietin level when available.

• For myelofibrosis avoid ESA in transfusion‑dependent patients or those with baseline Hb ≥ 10 g/dL unless compelling rationale documented.
• Include prior transfusion frequency and response expectations.

Required supporting lab and dosing conversion information

Include laboratory reference ranges (serum iron, ferritin) and the epoetin‑to‑darbepoetin conversion table in the documentation when relevant to dosing/conversion requests.

• Append Appendix B reference ranges and Appendix C conversion table when submitting conversion requests.

Supporting literature

Attach bibliographic references, clinical trials, guideline citations, and product prescribing information to support medical necessity determinations when requesting authorization for less common or investigational ESA uses.

• Relevant sources include Cochrane NMA, NCCN, ASCO/ASH guidelines, and manufacturer prescribing information.

Product prescribing information

Include product prescribing information (manufacturer PI) for the specific ESA product requested (eg, Epogen/Procrit/Retacrit, Aranesp, Mircera) as supporting documentation for product‑specific dosing and labeled indications.

• Manufacturer PI provides dose‑holding rules (eg, withhold if Hb exceeds labeled thresholds) and boxed warnings to inform authorization decisions.

Denial risk for experimental/investigational indications

Submission of ESAs for experimental or investigational indications listed in the policy may be denied; ensure requests are for FDA‑approved or guideline‑supported indications with supporting evidence.

• Examples of experimental/non‑covered uses include anemia of prematurity, prophylactic prevention of chemotherapy‑induced anemia, sepsis‑associated anemia, sickle cell anemia, and out‑of‑hospital cardiac arrest.

Risk when Hb targets exceeded

Use of ESAs to achieve or maintain hemoglobin targets above recommended levels (eg, exceeding ~11–12 g/dL or initiating therapy contrary to labeling) is associated with increased mortality and cardiovascular risk and may trigger denial or requirement for justification.

• FDA and trial data show higher risks when targeting Hb >11 g/dL; use the lowest dose to avoid transfusion and follow dose‑hold rules for Hb rises >1 g/dL in 2 weeks.

Conditions triggering noncoverage per CMS

CMS has determined ESAs are not reasonable and necessary for multiple conditions (eg, anemia due to cancer treatment with uncontrolled hypertension; anemia associated only with radiotherapy; anemia due to nutritional deficiencies, hemolysis, bleeding, bone marrow fibrosis; prophylactic use to prevent chemotherapy‑induced anemia), which may lead to noncoverage determinations.

• Prior authorization should exclude ESA use for CMS‑listed noncovered conditions unless compelling evidence and case review justify exception.

Clinical caution and labeling adherence

Authorization reviewers will apply clinical caution and require adherence to FDA labeling — avoid ESA use in cancer patients not receiving concurrent chemotherapy (except select low‑risk MDS) and discontinue if non‑responsive after 6–8 weeks.

• Ensure blood pressure is controlled prior to initiation and monitored during therapy; withhold for uncontrolled hypertension or prior antibody‑mediated PRCA.

Safety-related denial risk

Safety signals (increased thromboembolic events, hypertension, and possible increased mortality) may prompt denial or require explicit justification and monitoring plans when ESAs are requested.

• Cancer trials report ↑ VTE risk (~1.55‑fold) and potential mortality signals; include mitigation and monitoring strategies in authorization requests.

Ineffective indication denial risk

Use of ESAs for indications demonstrated ineffective (eg, traumatic brain injury) is at high risk of denial; provide robust supporting evidence if seeking coverage for such indications.

• TBI trials did not show neurological benefit and may increase adverse events; these uses are considered not medically necessary in policy.

Thrombosis risk / dosing caution

Exercise caution due to thrombosis risk; prior authorization may require documentation that the lowest ESA dose will be used to avoid transfusion and that ESA will be held if hemoglobin rises rapidly or exceeds label thresholds.

• NCCN/CMS/FDA guidance: hold ESA when Hb ≥10 g/dL in some COVID guidance examples and reduce dose if Hb approaches 11–12 g/dL per product labeling.
• Document VTE prophylaxis plan in perioperative contexts where ESA used.

OHCA safety signal

Out‑of‑hospital cardiac arrest (OHCA) indication carries a safety signal: trials showed no benefit and higher serious adverse events (notably thrombotic complications); requests for this indication are expected to be denied.

• Phase III OHCA trial: serious AEs 22.6% with EPO vs 14.9% control; thrombotic complications 12.4% vs 5.8%.

Alignment with FDA-approved indications

Prior authorization must align ESA use with FDA‑approved indications and recognized brands; off‑label uses described in the background (eg, neuroprotection, TBI) require strong supporting rationale.

• Append FDA‑approved indication table (Appendix A) and product PI to support requested use.

This section contains only references

This references section contains only citations and does not itself establish authorization or denial triggers; use the substantive policy sections and prior authorization module for determinations.

Safety advisory-related denial risk

FDA safety communications and advisories (labeling changes, boxed warnings, dosing modifications) represent safety‑related coverage risks; documentation must show adherence to current FDA dosing and monitoring guidance.

• FDA modified dosing recommendations (2011) advising initiation when Hb <10 g/dL and dose reduction/ interruption when Hb approaches/exceeds 11 g/dL.
• Include evidence of boxed‑warning counseling and monitoring plans in authorization requests.